Effective dosing of l-carnitine in the secondary prevention of cardiovascular disease: A systematic review and meta-analysis

53Citations
Citations of this article
97Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: L-carnitine supplementation has been associated with a significant reduction in all-cause mortality, ventricular arrhythmia, and angina in the setting of acute myocardial infarction (MI). However, on account of strict homeostatic regulation of plasma L-carnitine concentrations, higher doses of L-carnitine supplementation may not provide additional therapeutic benefits. This study aims to evaluate the effects of various oral maintenance dosages of L-carnitine on all-cause mortality and cardiovascular morbidities in the setting of acute MI. Methods: After a systematic review of several major electronic databases (PubMed, EMBASE, and the Cochrane Library) up to November 2013, a meta-analysis of five controlled trials (n = 3108) was conducted to determine the effects of L-carnitine on all-cause mortality and cardiovascular morbidities in the setting of acute MI. Results: The interaction test yielded no significant differences between the effects of the four daily oral maintenance dosages of L-carnitine (i.e., 2g, 3g, 4g, and 6g) on all-cause mortality (risk ratio [RR] = 0.77, 95% CI [0.57-1.03], P = 0.08) with a statistically insignificant trend favoring the 3g dose (RR = 0.48) over the lower 2g dose (RR = 0.62), which was favored over the higher 4g and 6g doses (RR = 0.78, 0.78). There was no significant differences between the effects of the daily oral maintenance dosages of 2g and 6g on heart failure (RR = 0.53, 95% CI [0.25-1.13], P = 0.10), unstable angina (RR = 0.90, 95% CI [0.51-1.58], P = 0.71), or myocardial reinfarction (RR = 0.74, 95% CI [0.30-1.80], P = 0.50). Conclusions: There appears to be no significant marginal benefit in terms of all-cause mortality, heart failure, unstable angina, or myocardial reinfarction in the setting of acute MI for oral L-carnitine maintenance doses of greater or less than 3g per day.

Cite

CITATION STYLE

APA

Shang, R., Sun, Z., & Li, H. (2014). Effective dosing of l-carnitine in the secondary prevention of cardiovascular disease: A systematic review and meta-analysis. BMC Cardiovascular Disorders, 14(1). https://doi.org/10.1186/1471-2261-14-88

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free